Brent Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brent Robinson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ian A. Shiels
School of Biomedical Sciences, Research Road, University of Queensland, St. Lucia, Queensland, 4072, Australia
1 shared publication - Jaclyn Costello
The School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, 20 Cornwall Street, Woolloongabba, Brisbane, Queensland, 4102, Australia; Pharmacy Department, Ground Floor Redcliffe Hospital, Anzac Avenue, Redcliffe, Queensland, 4020, Australia
1 shared publication - Liam G. Coulthard
School of Biomedical Sciences, University of Queensland, Australia
1 shared publication - Stephen M. Taylor
School of Biomedical Sciences, University of Queensland, Brisbane, Queensland 4072, Australia
1 shared publication - Trent Martin Woodruff
University of Queensland
1 shared publication
Latest Publications
- Open Access
- 14 March 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (2) , R42
Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis
Previously, secretory phospholipase A2 (sPLA2) inhibition has been used as an adjunct to conventional rheumatoid arthritis therapy in human clinical trials without significant improvement of arthritic pathology. In this study, we compared the efficacy of a potent and orally active group IIa secretory phospholipase A2 inhibitor (sPLA2I) to conventional anti-arthritic agents; infliximab, leflunomide and prednisolone, in a rat model of antigen-induced arthritis.
- 14 March 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (2) , R42
Open AccessComparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis
Previously, secretory phospholipase A2 (sPLA2) inhibition has been used as an adjunct to conventional rheumatoid arthritis therapy in human clinical trials without significant improvement of arthritic pathology. In this study, we compared the efficacy of a potent and orally active group IIa secretory phospholipase A2 inhibitor (sPLA2I) to conventional anti-arthritic agents; infliximab, leflunomide and prednisolone, in a rat model of antigen-induced arthritis.